Overview

• U.S. endocrine drugmaker's Q1 revenue rose sharply on Palsonify launch

• Net loss widened from prior year as R&D and SG&A expenses increased

• Company reported strong Palsonify adoption, with 232 enrollment forms and growing prescriber base

Outlook

• Crinetics expects 2026 GAAP operating expenses between $600 mln and $650 mln

• Company sees 2026 non-GAAP operating expenses between $480 mln and $520 mln

• Crinetics plans to initiate Phase 2/3 atumelnant trial for Cushing’s syndrome in Q2 2026

Result Drivers

• PALSONIFY ADOPTION - Co said rapid uptake of Palsonify drove Q1 net product revenue, with 232 enrollment forms and 263 unique prescribers in first two quarters of launch

• REIMBURSEMENT ENVIRONMENT - Co said about 70% of Palsonify patients at end of Q1 were on reimbursed therapy as payer coverage increased

Company press release: ID:nGNX8LHJk2

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Net Income		-$127.85 mln
Q1 Basic EPS		-$1.23
Q1 Operating Expenses		$151.11 mln
Q1 Operating Income		-$140.38 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Crinetics Pharmaceuticals Inc is $88.00, about 111% above its May 6 closing price of $41.71

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.